Galena Biopharma, Inc. was a big mover last session, as its shares rose over 19% on the day. The stock rallied after the FDA granted a Fast Track designation to the company’s breast cancer drug, NeuVax. This also led to far more shares changing hands than in a normal session. Yesterday’s rally continues the uptrend for the company, as the stock is now up 60% in the past one-month time frame.
Over the last 30 days, the company witnessed two negative estimate revisions and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts.
Galena Biopharma currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.
A better-ranked biomedical stock is HESKA CORP , sporting a Zacks Rank #1 (Strong Buy).
Is GALE going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Galena Biopharma, Inc. was a big mover last session, as its shares rose over 19% on the day. The stock rallied after the FDA granted a Fast Track designation to the company’s breast cancer drug, NeuVax. This also led to far more shares changing hands than in a normal session. Yesterday’s rally continues the uptrend for the company, as the stock is now up 60% in the past one-month time frame.
Over the last 30 days, the company witnessed two negative estimate revisions and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts.
Galena Biopharma currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.
A better-ranked biomedical stock is HESKA CORP , sporting a Zacks Rank #1 (Strong Buy).
Is GALE going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>